BRIA-ABC: Bria-IMT plus Immunotherapy for Patients with Pre-Treated Metastatic Breast Cancer
Condition: Breast Cancer
Sponsor: BriaCell Therapeutics Corporation
Full Title
BC-IMT-04: Randomized, Open-label Study of the Bria-IMT Regimen and Check Point Inhibitor vs Physician’s Choice in Advanced Metastatic Breast Cancer
Study Treatment
GM-CSF-secreting breast cancer vaccine SV-BR-1-GM in combination with anti-PD1 immunotherapy retifanlimab-dlwr
Eligibility/Info
Eligible patients will have one of the following prior treatment histories:
- HR+/HER2-: Previously treated with at least 2 prior chemotherapy or targeted therapy regimens
- HER2+: Previously treated with at least 3 treatment regimens including 2 anti-HER2 therapies
- TNBC: Exhausted all standard of care therapies known to confer clinical benefit
- HER2-Low: Previously treated with at least 1 anti-HER2 therapy in addition to the appropriate HR status therapies
- Actionable Mutation: Patients with an actionable mutation must have been treated with appropriate targeted therapy
Contact
For more information about this or any other study, please contact the NYCBS Research Department:
Email: ResearchRecruitment@nycancer.com
Telephone: 631-675-5075
HALO Messaging App: "Research Team"
